This question arises as the experimental peptide gains online attention, yet no clinical evidence links BPC-157 to erectile dysfunction
Concerns That Require Attention Cancer history: GH and IGF-1 promote cell proliferation
Clinical trials support semaglutide up to 2.4 mg weekly for weight loss (Wegovy indication)

URLs: Tickets: Brochure: Prices: Drug Developer Pricing* - Conference + 2 Workshops : USD 4197.00, Drug Developer Pricing* - Conference + 1 Workshop: USD 3598.00, Drug Developer Pricing* - Conference Only: USD 2999.00, Academic Pricing** - Conference + 2 Workshops: USD 3597.00, Academic Pricing** - Conference + 1 Workshop Only: USD 3098.00, Academic Pricing** - Conference Only: USD 2599.00, Solution Provider Pricing - Conference + 2 Workshops: USD 5097.00, Solution Provider Pricing - Conference + 1 Workshop: USD 4398.00, Solution Provider Pricing - Conference Only: USD 3699.00 Speakers: Adam Bell, Vice President, Translational Medicine and Regulatory Affairs, Neuraly, Andrew Young, Chief Scientific and Medical Officer, I2O Therapeutics, Belle van Rosmalen, Director - Incretin Outcomes, Eli Lilly and Co., Damian Bialonczyk, Global Medical Lead - Metabolism, Roche, David Glass, Vice President - Research, Regeneron, Elisa Araldi, Professor, University of Parma, Hong Chen, Director - Search and Evaluation, Novo Nordisk, Jason Mastaitis, Sr

Phase 2 trial data showed retatrutide was generally well-tolerated, with a safety profile similar to other GLP-1 medications (semaglutide, tirzepatide)